In this study, with the use of novel inflammasome inhibitor CRID3, we have demonstrated the inhibition of multiple inflammasomes associated genes expression as well as decreased caspase-1 and IL-1β levels in an in vitro AD cell culture model. This evidence concerns the gene CASP1 and Alzheimer disease.